High dose Intravenous Gammaglobulins in Autoimmune Disorders: Mode of action and Therapeutic Uses

References

• Hassig A. Requirements for modern intravenous immunoglobulin preparations and their safe clinical use. Triangle 1987; 26: 23–32
   Google Scholar
• Colomb M G, Drauet C, Law D TS, Painter R H. Structural and biological properties of three intravenous immunoglobulin preparations. Clinical Use of Intravenous Immunoglobulin, A Morell, U E Nydegger. Academic Press, London 1986; 27–36
   Google Scholar
• Steele R W, Burks W, Jr., Williams L W. Intravenous immunoglobulin: new clinical applications. Ann Allergy 1988; 60: 89–94
   Google Scholar
• Appropriate use of human immunoglobulin in clinical practice. IUIS/WHO Notice. Clin Exp Immunol 1983; 52: 417–22
   Google Scholar
• Berkman S A, Lee M L, Gale K P. Clinical uses of intravenous immunoglobulins. Sem Hemat 1988; 25: 140–58
   PubMed Web of Science ®Google Scholar
• Burks A W, Sampson H A, Buckley R H. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. N Eng J Med 1986; 314: 560–4
   PubMed Web of Science ®Google Scholar
• Lever A M, Brown D, Webster A DB, Thomas H C. Non-A, Non-B hepatitis occurring in agammag-lobulinemic patients after intravenous immunoglobulin. Lancet 1984; 2: 1062–4
   PubMed Web of Science ®Google Scholar
• Lane R S. Non-A, Non-B hepatitis from intravenous immunoglobulin. Lancet 1983; 2: 974–5
   PubMed Web of Science ®Google Scholar
• Lockburn I. Possible transmission of non-A, non-B hepatitis. Vox Sang 1986; 51: 254
   Google Scholar
• Rousell R H, Good R A, Pirofsky B, Schiff R I. Non-A, Non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: A retrospective survey. Vox Sang 1988; 54: 6–13
   Google Scholar
• Safety of therapeutic immune globulin preparations with respect to transmission of HTLV-III/LAV infection. MMWR 1986; 35: 231–3
   PubMedGoogle Scholar
• Cross A S, Alving B M, Sadoff J C, Baldwin P, Terebelo H, Tong D. Intravenous immune globulin: A cautionary note. Lancet 1984; 1: 912
   Google Scholar
• Barandun S, Morell A, Skvaril F. Clinical experiences with immunoglobulin for intravenous use. Immunoglobulins: Characteristics and Uses of Intravenous Preparations, B M Alving, J S Finlayson. U.S. Dept. Health Human Services. 1980; 31–5, CFDA-80–9005
   Google Scholar
• Imbach I, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228–31
   PubMed Web of Science ®Google Scholar
• Hilgartner M N, Bussel J. Use of intravenous gammaglobulin for the treatment of autoimmune neutropenia in childhood and autoimmune hemolytic anemia. Amer J Med 1987; 83: 25–9, (Supp 4A)
   PubMed Web of Science ®Google Scholar
• Kurlander R, Coleman R E, Moore J, Gockerman J, Rosse W, Siegal R. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gammaglobulin in the treatment of immune thrombocytopenic purpura in adults. Amer J Med 1987; 84: 17–24, supp 4A
   Google Scholar
• McGuire W A, Yang H H, Bruno E, Brandt J, Briddell R, Coates T D, Hoffman R. Treatment of antibody-mediated pure red cell aplasia with high-dose intravenous gammaglobulin. New Eng J Med 1987; 317: 1004–8
   PubMedGoogle Scholar
• Bussell J B, Goldman A, Imbach P, Schulman I, Hilgartner M W. Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin. J Pediat 1985; 106: 885–90
   Google Scholar
• Newland A C. Intravenous immunoglobulin therapy in chronic idiopathic thrombocytopenia purpura. Clinical Use of Intravenous Immunoglobulins, A Morrell, U E Nydegger. Academic Press, London 1986; 203–16
   Google Scholar
• Ballin A, Andrew M, Ling E, Perlman M, Blanchette V. High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia. J Pediat 1988; 112: 189–92
   Google Scholar
• Newland A C, Treleaven J G, Minchinton R M, Waters A H. High dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1: 84–7
   PubMed Web of Science ®Google Scholar
• Baumann M A, Manitove J E, Aster R H, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Inter Med 1986; 104: 808–9
   Google Scholar
• Cohen J I. Gammaglobulin for idiopathic thrombocytopenic purpura. New Eng J Med 1982; 307: 1151
   Google Scholar
• Hollenberg J P, Subak Ferry LL, Bussel J B. Cost-effectiveness of splenectomy versus intravenous gammaglobulin in treatment of chronic immune thrombocytopenic purpura in childhood. J Pediat 1988; 112: 530–9
   PubMedGoogle Scholar
• Koren G, Lavi S, Rose U, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediat 1986; 108: 388–92
   PubMed Web of Science ®Google Scholar
• Lin C, Hwang Y. B. Serial immunologic studies in patients with mucocutaneous lymph node syndrome (Kawasaki disease). Ann Allergy 1987; 59: 291–7
   Google Scholar
• Newburger J W, Takahashi M, Burns J C, Beiser A S, Chung K J, Duffy C E, et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. New Eng J Med 1986; 315: 341–7
   PubMed Web of Science ®Google Scholar
• Nagashima M, Matsushima M, Matsuaka H, Ogawa A, Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. J Pediat 1987; 110: 710–2
   PubMed Web of Science ®Google Scholar
• Bierman F Z, Gersony W M. Kawasaki disease: clinical prospective. J Pediat 1987; 111: 789–92
   Google Scholar
• Leung D YM, Burns J C, Newburger J W, Geha R S. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79: 468–72
   PubMedGoogle Scholar
• Pollack S. Cunningham-Rundles C, Smithwick EM, Barandun S, Good RA. High-dose intravenous gammaglobulin for autoimmune neutropenia. New Eng J Med 1982; 307: 253
   PubMed Web of Science ®Google Scholar
• Breedveld F C, Brand A, Van Aken W G. High dose intravenous γ-globulin for Felt's syndrome. J Rheumatol 1985; 12: 702–7
   Google Scholar
• Bussel J B, Lalezari P, Fiking S. Intravenous treatment with γ-globulin of autoimmune neutropenia of infancy. J Pediat 1988; 112: 298–301
   PubMed Web of Science ®Google Scholar
• Macintyre E A, Linch D C, Macey M G, Newland A C. Successful response to intravenous immunoglobulin in autoimmune haemolytic anemia. Br J hematol 1985; 60: 387–8
   PubMedGoogle Scholar
• Bussel J B, Cunningham-Rundles C, Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose γ-globulin. Vox Sang 1987; 51: 264–9
   Google Scholar
• Clauvel J P, Vainchenker W, Herrera A, Dellagi K, Uinci G, Tabilio A, Lacombe C. Treatment of pure red cell aplasia by high dose intravenous immunoglobulin. Brit J Haemat 1983; 56: 380–2
   Google Scholar
• Etzioni A, Atias D, Pollack S, Hazani A, Vardi P, Levy J, Benderly A. Intramuscular gammaglobulin therapy in a child with hypoparathyroidism and pure red cell aplasia. Amer J hematol 1986; 16: 409–14
   Google Scholar
• Finn T H, Wang J C, Hong K J. High dose intravenous γ-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura. Arch Inter Med 1987; 147: 2165–7
   PubMedGoogle Scholar
• Etzioni A, Hazani A, Pollack S, Erde P, Benderly A. High dose intravenous gammaglobulin in a child with recurrent hemolytic-uremic syndrome. XII International Congress of Allergology and Clinical Immunology, MontreuxSwitzerland, 1988
   Google Scholar
• Seifried E, Gaedicke G, Pindur G, Rasche H. The treatment of hemophilia A inhibitor with high dose intravenous immunoglobulin. Blut 1984; 48: 397–401
   PubMedGoogle Scholar
• Sultan Y, Rossi F, Kazatchkine M D. Recovery from anti VIII.C autoimmune disease is dependent on generation of antiidiotypes against anti VIII:C autoantibodies. Proc Nat Acad Sci USA 1987; 84: 828–31
   PubMed Web of Science ®Google Scholar
• Arzura E L, Bick A, Brunner N G, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myastenia gravis. Arch Intern Med 1986; 146: 1365–8
   Google Scholar
• Cook L, Howard J F, Folds J D. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myastenia gravis. J Clin Immunol 1988; 8: 23–31
   PubMedGoogle Scholar
• Liblau R, Gajdos P, Bustarret A F, el-Habib R, Bach J F, Morel E. The use of intravenous gammaglobulin in myastenia gravis; interaction with myastenic sera. Immunointervention in autoimmune disease. Paris June, 16–19, 1988
   Google Scholar
• Godard W, Roujeau J C, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Inter Med 1986; 103: 964–5
   Google Scholar
• Gaedicke G, Teller W M, Kohne E, Dopfer R, Niethanmer D. IgG therapy in systemic lupus erythematosus: two case reports. Blut 1984; 48: 387–90
   PubMedGoogle Scholar
• Pedersen F K. Systemic juvenile rheumatoid arthritis treated with intravenous immunoglobulin. Immunointervention in Autoimmune Disease. Paris June, 16–19, 1988
   Google Scholar
• Roifman C M, Laxer R M, Gelfand E W, Silverman I J. Treatment of systemic juvenile arthritis with intravenous serum gammaglobulin. Clin Res 1988; 36: 446A
   Google Scholar
• Heinze E, Thon A, Vetter U, Gaedicke G, Zuppinger K. Gammaglobulin therapy in 6 newly diagnosed diabetic children. Acta Paediat Scand 1985; 74: 605–6
   Google Scholar
• Ariizumi M, Bala K, Shiihara H. High dose gammaglobulin for intractable childhood epilepsy. Lancet 1983; 2: 162–3
   Google Scholar
• Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose intravenous gammaglobulin. New Eng J Med 1982; 306: 1254–8
   PubMed Web of Science ®Google Scholar
• Bussel J B, Kimberly R P, Inman R D. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62: 480–6
   PubMed Web of Science ®Google Scholar
• Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2: 193–5
   PubMed Web of Science ®Google Scholar
• Kimberly R P, Salmon J E, Bussel J B, Crow M K, Hilgartner M W. Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol 1984; 132: 745–50
   PubMed Web of Science ®Google Scholar
• Bussel J B, Pahwa S, Porges A, Cunningham-Rundles S, Koziner B, Morell A, Barandum S. Correlation of in vivo antibody synthesis with the outcome of intravenousgammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. J Clin Immunol 1986; 6: 50–6
   PubMedGoogle Scholar
• Bystryn J C, Graf M W, Uhr J W. Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med 1970; 132: 1279–87
   PubMed Web of Science ®Google Scholar
• Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136: 1407–13
   Google Scholar
• Nydegger U E, Spycher M O. Polyclonal polyspecific antibody mixtures from random donors as therapeutic tools in autoimmune disease. Clinical Use of Intravenous Immunoglobulin, A Morrell, U E Nydegger. Academic Press, London 1986; 431–41
   Google Scholar
• Tsubakio T, Kurata Y, Katagiri Sand. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high-dose gammaglobulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 1983; 53: 697–702
   PubMed Web of Science ®Google Scholar
• White W B, Desbonnet C R, Ballow M. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia. Amer J Med 1987; 83: 431–6
   Google Scholar
• Delfraissy J F, Tchernia G, Laurian Y, Wallon C, Golanaud P, Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Brit J haemat 1985; 60: 315–22
   PubMed Web of Science ®Google Scholar
• Sultan Y., Maisonneuve P, Kazatchkine M D, Nydegger U E. Anti-idiotypic suppression of autoantibodies to factor VIII by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765–8
   PubMed Web of Science ®Google Scholar
• Nydegger U E. Selected pathophysiological aspects of autoimmune disease as the basis for transfusion therapy with polyclonal antibody mixtures. Triangle 1984; 23: 133–40
   Google Scholar
• Rossi F, Brand A, Kazachkine M D. Anti-idiotypic suppression of autoantibodies with polyspecific normal immunoglobulins. Immunointervention in Autoimmune Disease. ParisFrance 1988
   Google Scholar
• Etzioni A, Pollack S, Benderly A. Gammaglobulin for antibody mediated pure red cell aplasia. New Eng J Med 1988; 318: 994
   Google Scholar